uMotif evolves leadership team with appointment of Steve Rosenberg as CEO

Ad - Bora Pharmaceuticals

uMotif, a leading eClinical platform provider powering patient-centric research, announced a reorganisation of its leadership structure as Steve Rosenberg is appointed CEO. The announcement forms part of a wider evolution of uMotif’s executive team, with Julia Lakeland also joining as Chief Product Officer. The transfer of leadership signals a new phase for uMotif as it prepares to scale and grow, bolstering its commitment to developing fit-for-purpose technologies that serve the needs of patients and sponsors.

Rosenberg’s career in life science and healthcare spans more than 40 years. He has led the development and deployment of cloud-based solutions with a focus on driving more integrated approaches to patient-centric trial management. Rosenberg was most recently Senior Vice President and General Manager of Oracle Health Sciences. Prior to that he was the visionary behind the integrated clinical technology suite introduced by Phase Forward which was acquired by Oracle in 2010. Rosenberg joined uMotif’s board earlier this year.

“Since uMotif was founded, the team has brought a unique patient-centred approach to trial management, transforming how those taking part in clinical research interact and engage with their care providers,” comments Steve Rosenberg, CEO, uMotif. “I look forward to leading the business through the next stage of growth and building further on the strength of its applications.”

Established in 2012, uMotif has developed an eClinical platform that meets the real needs of patients, making trial participation and data capture as simple as possible. The evolvement of the organisation’s leadership team has been facilitated by co-founders Bruce Hellman and Ben James, who will now take on the roles of Chief Patient Officer and Head of Human Centered Design respectively.

“uMotif was established with the aim of developing technologies that could better serve the needs of patients through improved engagement,” said Bruce Hellman, Chief Patient Officer and Co-Founder of uMotif. “As we move into the next phase in our growth it is the right time to establish a new leadership structure and roadmap for the business. Steve and Julia both bring deep expertise in areas key to the future success of uMotif and I look forward to working with them both as we continue to lead the way in putting patients at the core of clinical research.”

Julia Lakeland, formerly of Parexel, will now assume the role of uMotif’s Chief Product Officer. With more than 20 years’ experience in the industry, Lakeland is passionate about improving the patient experience in clinical trials and delivering products and services that enable new treatments to be brought to market safely and quickly.

Commenting on the appointment, Lakeland said, “The digital transformation of clinical trials has never been at a more crucial time. Sponsors are looking for partners that can provide excellent service and pragmatic technologies that can support the shift towards more decentralised clinical trials. I am looking forward to working closely with the highly capable team to ensure we deliver the best platform to meet the needs of customers and patients in this changing era of research.”

About uMotif

uMotif’s mission is to put patients at the centre of clinical research. Designed with patients for patients, the uMotif patient-centric eClinical platform powers site-based to fully decentralised clinical, real-world, and post-marketing research. By engaging patients and healthcare professionals, uMotif is trusted by global pharmaceutical companies, biotechs, CROs, and academic institutions to capture eConsent and large volumes of ePRO, symptom, and wearable device data.